ADMA Biologics, Inc. (ADMA) Income Statement

The sharp deceleration from triple-digit growth rates in 2024 to low-single-digit in 2026Q2 indicates a transition from a low-base recovery to a more sustainable, product-driven phase. The 19.6% year-over-year growth in 2025Q4, despite a sequential dip, suggests that ASCENIV's market penetration is becoming the primary growth lever, as opposed to one-off factors. Investors should monitor whether the 2.0% growth in 2026Q2 is a temporary trough or a sign of market saturation, especially given the maintained guidance.

The consistent upward trajectory in gross margin, despite quarterly fluctuations, indicates a structural improvement in product mix rather than cost reduction. The 2025Q3 dip to 56.3% likely reflects higher plasma costs or batch timing, but the subsequent recovery to 69.4% suggests management's ability to maintain pricing power. This margin profile is significantly above peers like Grifols (35.7%), underscoring ADMA's niche positioning in high-titer immunoglobulins.

The operating income growth outpaced revenue growth in most quarters, particularly in 2025Q1 where revenue grew 40.2% and operating income grew 60.1%. This suggests that fixed costs are being spread over a larger revenue base, and R&D expenses have remained minimal, allowing more revenue to flow to the bottom line. The 2026Q2 operating margin of 42.2% is near the peak, but the slight sequential decline from 43.9% warrants monitoring for potential cost pressures.

The overall downward trend in COGS ratio reflects improved manufacturing efficiency and product mix, but the volatility suggests that plasma procurement costs and production yields are not fully under control. SG&A has grown steadily, from $15.6M to $26.7M, but as a percentage of revenue it has declined from 19.0% to 21.5%, indicating that overhead is being managed effectively. R&D remains minimal, consistent with a commercial-stage company, but the increase to $6.0M in 2026Q2 may signal renewed investment in pipeline or manufacturing improvements.

The transition from a development-stage to a profitable commercial operation is evident in the margin expansion from 2024Q1 to 2024Q3, where gross margin rose from 47.8% to 49.8% and operating margin from 26.7% to 33.1%. This period likely reflects the full commercialization of ASCENIV and the scaling of the Boca Raton facility. The subsequent quarters have built on this foundation, with margins reaching new highs, suggesting that the company has achieved a sustainable cost structure and product mix.